Recent News

• 02.11.2025 - AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
• 02.11.2025 - AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
• 02.07.2025 - AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
• 02.07.2025 - AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
• 02.05.2025 - Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
• 02.05.2025 - Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
• 02.05.2025 - Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
• 01.23.2025 - AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

Recent Filings

• 02.11.2025 - EX-99.1 EX-99.1
• 02.11.2025 - EX-99.1 EX-99.1
• 02.11.2025 - 8-K Current report
• 02.11.2025 - 8-K Current report
• 02.07.2025 - 8-K Current report
• 02.07.2025 - EX-99.1 EX-99.1
• 02.07.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 02.05.2025 - EX-99.1 EX-99.1
• 02.05.2025 - 8-K Current report
• 02.03.2025 - 4 Statement of changes in beneficial ownership of securities